Pharmaxis touts progress in cystic fibrosis study

By Ruth Beran
Monday, 19 December, 2005

Sydney-based drug developer Pharmaxis (ASX:PXS, Nasdaq:PXSL) has begun the dosing phase of its phase II clinical trial in patients with cystic fibrosis.

The study, which aims to determine the benefits of Bronchitol in children also receiving the market leading treatment, rhDNase, is being conducted at two sites in the UK.

The 42 patients enrolled in the study will receive three months treatment with each of three different therapies -- Bronchitol alone, both Bronchitol and rhDNase together and rhDNase alone. The trial will measure changes in lung function, airway inflammation, infections, and quality of life.

Full patient recruitment is expected to take about eight months

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd